Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 2, 2025Molecular and Clinical OncologyOpen Access

Taking the ‘low’ into consideration: Discussions on redefining HER2 status in breast cancer (Review)

View Full Paper
Ask AI
Bookmark
Share

Authors

AGAlexandros GeorgiouESEvangelia Anna SpiteriDSDemetrios�� Spandidos

Discussion

Loading...

Member takes

Overview

Review discusses HER2-low tumors, their biological significance, and therapeutic implications for breast cancer management.

Key Points

  • HER2-low tumors are emerging as a significant subtype of breast cancer, distinct from HER2-positive and HER2-negative classifications.
  • Technological advancements in HER2 testing have improved the detection and understanding of HER2-low tumors and their unique characteristics.
  • Clinical trials demonstrating the effectiveness of trastuzumab-deruxtecan suggest that HER2-low tumors may benefit from specific targeted therapies.
  • Revising guidelines to incorporate HER2-low tumors could optimize patient treatment strategies and enhance overall clinical outcomes.

Cite This Study

Georgiou et al. (2025) studied this question.

synapsesocial.com/papers/68de79595b556a9128e1a46fhttps://doi.org/10.3892/mco.2025.2898
View Full Paper
Ask AI
Bookmark
Share